– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025 Expect data readouts for DISC-0974 program in H2 2025, including
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the
– Loan Originations of $1.3 Billion – – Net Income of $3.2 Million – – Diluted Earnings Per Share of $0.23 – MURRAY, Utah, April 30, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced results for the quarter ended March 31, 2025. First
NORTH LIBERTY, Iowa, April 30, 2025 (GLOBE NEWSWIRE) — Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the three months ended March 31, 2025. Three months ended March 31, 2025: Operating Revenue of $219.4 million, Net Loss of $13.9 million, Basic Loss per Share of $0.18, Operating Ratio of 106.8% and 107.1% Non-GAAP
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson’s disease (PD) Additional ACI-7104.056 Phase 2 interim
INDIANAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, reported today its operating results for the first quarter ended March 31, 2025. For the quarters ended March 31, 2025 and 2024, net income attributable to common shareholders was